Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . KELUN KELUN - BIOTECH BIOTECH 科伦博泰 Sichuan Kelun - Biotech Biopharmaceutical Co. , Ltd. 四 川科倫博泰 生物 醫藥 股份有限公司 ( A joint stock company incorporated in the People's Republic of China with limited liability ) ( Stock Code : 6990 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30 , 2026 The Board is pleased to announce the unaudited condensed consolidated interim results of the Group for the six months ended June 30 , 2026 , together with comparative figures for the six months ended June 30 , 2025. The independent auditor of the Company has carried out a review of the interim financial information in accordance with the Hong Kong Standard on Review Engagements 2410 “ Review of Interim Financial Information Performed by the Independent Auditor of the Entity " , issued by the HKICPA . Unless otherwise defined herein , capitalized terms used in this announcement shall have the same meanings as those defined in the Prospectus . FINANCIAL HIGHLIGHTS Revenue Gross profit Research and development expenses Profit / ( loss ) for the period Adjusted Profit / ( loss ) for the period¹ Cash and financial assets² Total equity Debt - to - asset ratio³ Six months ended June 30 , 2026 RMB'000 ( Unaudited ) 2025 RMB'000 ( Unaudited ) Period to period change 978,340 950,445 2.9 % 736,903 659,988 11.7 % ( 768,434 ) ( 611,539 ) 25.7 % 388,007 ( 145,175 ) 479,371 ( 69,398 ) As at As at June 30 , December 31 , 2026 2025 4,783,102 4,559,358 4.9 % 5,336,851 15.6 % 4,867,070 18.7 % 9.7 % 1 2 3 Calculated by excluding equity - settled share - based payment from Profit / ( loss ) for the period . The equity- settled share - based payment was RMB91.4 million and RMB75.8 million for the six months ended June 30 , 2026 and 2025 , respectively . Comprises cash and cash equivalents , restricted deposits , financial assets measured at fair value through other comprehensive income , financial assets measured at fair value through profit or loss and financial assets measured at amortized cost . Calculated by dividing the total liabilities by the total assets . -1-